Analyst reports.
This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.
Analyst Reports 2024
Analyst Reports 2024
June 28th 2024
Bell Potter - Combo data supportive in HNSCC; Retain Buy, A$0.75 (Analyst: Thomas Wakim)
June 28th 2024
Canaccord Genuity - Headstrong conviction in Efti's potential clinical impact; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)
June 27th 2024
Maxim - An Imbalance in the 1L H&N Control Arm Data but the Overall Efti + Keytruda Combo is Positive and Consistent; Reiterate Buy, $12 PT (Analyst: Jason McCarthy, Ph.D.)
June 27th 2024
Ladenburg Thalmann - Our Thoughts on TACTI-003 Data; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)
June 27th 2024
Capital One - IMMP: Cohort Imbalance Muddies Cohort A Topline Data, But Could Still Improve; Rated OW; $10 PT (Analyst: Naureen Quibria, PhD)
June 27th 2024
CLSA - TACTI-003: Cohort A data; Cohort A delivers a ‘pass’ mark, but patient imbalances cloud comparison; Retain BUY, A$0.95 PT (Analyst: Andrew Paine)
June 27th 2024
Baird - Efti Shows Favorable Trend on ORR in Phase 2b Trial in HNSCC; Maintain OP, $6 PT (Analyst: Joel L. Beatty, MD)
June 12th 2024
Maxim - Is Efti the Answer for Merck's Keytruda Franchise? Going to P3 in 1L Lung is a Big Deal; Maintain Buy, Raise PT to $12 (Analyst: Jason McCarthy, Ph.D.)
June 6th 2024
Baird - Collab with Merck Provides Downside Support Ahead of Phase 2 HNSCC Data; Maintain OP, $7 PT (Analyst: Joel L. Beatty, MD)
June 5th 2024
CLSA - Cap raise strengthens position; A$100m raise reduces sentiment risk ahead of key readout; Retain BUY, A$0.95 PT (Analyst: Andrew Paine)
May 17th 2024
Capital One - IMMP: No LAG(gard) Here, Efti’s Ready to Go Pivotal; Initiating at OW, $10 PT (Analyst: Naureen Quibria, PhD)
May 16th 2024
CLSA - Higher dosing showing promise; MBC efti+chemo dose escalation complete response, no safety concerns; Rated BUY, A$0.95 (Analyst: Andrew Paine)
May 15th 2024
Canaccord Genuity - Efti poster at ESMO: Continued safety is a win; Rated Buy, A$1 Price Target (Analyst: Elyse Shapiro)
May 3rd 2024
Bell Potter - More Great Data, Major Catalyst Nears; Maintain Buy, A$0.80 Valuation (Analyst: Thomas Wakim)
May 2nd 2024
Canaccord Genuity - Ticking all the boxes - initial positive read from efti in soft tissue sarcoma; Rated Buy, A$1 Price Target (Analyst: Elyse Shapiro)
April 30th 2024
Ladenburg Thalmann - 3Q FY2024: Bullish on Randomized Trial Readout; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)
April 29th 2024
Canaccord Genuity - Not LAG-ing Behind in the Immune Oncology Race; Initiating Coverage with a BUY Rating and A$1 tgt (Analyst: Elyse Shapiro)
April 24th 2024
Ladenburg Thalmann - TACTI-003 Interim Readout: Boosting Confidence in Head and Neck; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)
April 24th 2024
Maxim Group - Preliminary Data from TACTI-003 Outperforms Historical Control by 5x; Full ORR Data Expected Within C2Q24; Mtn Buy, $10 tgt (Jason McCarthy, PhD)
April 24th 2024
Baird - Encouraged by Efti Topline Results in PD-L1 Negative Head and Neck Cancer; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)
April 24th 2024
CLSA - 1L Head & Neck Cohort B ORR 5x higher vs Keytruda monotherapy; Response rate encouraging in difficult to treat patients, surprises to the upside (Analyst: Andrew Paine)
April 24th 2024
Jefferies - efti/pembro 5x ORR increase over pembro monoRx (Analyst: Dr David Stanton)
April 24th 2024
Bell Potter - Exceptional first taste of TACTI-003 data, 27% ORR ~5x higher than historical ORR of ~5%; Maintain Buy and increase Price Target to A$0.80 (Analyst: Thomas Wakim)
April 19th 2024
Ladenburg Thalmann - Autoimmune Program is Advancing into Clinic; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)
April 4th 2024
Bell Potter - Thoughts Ahead of TACTI-003 Readout; Maintain Buy, A$0.65 tgt (Analyst: Thomas Wakim)
March 27th 2024
CLSA - Checking in; Maintain Buy, A$0.95 tgt (Analyst: Andrew Paine)
March 6th 2024
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)
March 6th 2024
Baird - First Data on Highest Dose Ever of Efti Includes a Complete Response; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)
March 5th 2024
CLSA - Nearing the Checkpoint; Upcoming HNSCC trial readout & Ph3 NSCLC progress key focus in CY24; Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)
March 4th 2024
Bell Potter - Multiple Indications Advancing; Maintain Buy, Raise tgt to A$0.65 (Analyst: Thomas Wakim)
February 29th 2024